Neurocrine Biosciences reported $984.6M in Current Liabilities for its fiscal quarter ending in September of 2026.





Current Liabilities Change Date
AbbVie USD 43.1B 1.46B Sep/2026
Acadia Pharmaceuticals USD 332.22M 29.22M Sep/2026
Agios Pharmaceuticals USD 77.59M 7.37M Sep/2026
ALKERMES USD 651.93M 10.16M Sep/2026
Alnylam Pharmaceuticals USD 2.06B 550.49M Sep/2026
Amgen USD 23.23B 2.27B Sep/2026
Biogen USD 3.9B 18.7M Sep/2026
BioMarin Pharmaceutical USD 1.6B 59.17M Sep/2026
Cytokinetics USD 353.42M 171.99M Sep/2026
Enanta Pharmaceuticals USD 44.73M 3.83M Dec/2025
Exelixis USD 411.88M 49.95M Sep/2026
Gilead Sciences USD 12B 982M Sep/2026
Halozyme Therapeutics USD 476.09M 131.65M Sep/2026
Incyte USD 1.44B 125.72M Sep/2026
Ionis Pharmaceuticals USD 435.29M 119.65M Sep/2026
Nektar Therapeutics USD 57.71M 4.17M Mar/2026
Neurocrine Biosciences USD 984.6M 110.1M Sep/2026
Pfizer USD 31.73B 920M Sep/2026
Prothena USD 11.43M 224K Sep/2026
Regeneron Pharmaceuticals USD 6.2B 671.5M Sep/2026
Repligen USD 125.69M 6.97M Sep/2026
Rigel Pharmaceuticals USD 94.4M 7.76M Sep/2025
Sarepta Therapeutics USD 656.35M 153.44M Sep/2026
Teva Pharmaceutical Industries USD 15.42B 221M Sep/2026
Ultragenyx Pharmaceutical USD 389M 38M Sep/2026
Vertex Pharmaceuticals USD 5B 1.06B Sep/2026